Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Phase 2 Clinical Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy (XELOX) as First-line (1L) Treatment in Patients With MSS/pMMR Advanced Colorectal Cance

NCT06885385 is registered in ClinicalTrials.gov with Shanghai Junshi Bioscience Co., Ltd. as lead sponsor.

NCT NCT06885385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06885385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Phase 2 Clinical Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy (XELOX) as First-line (1L) Treatment in Patients With MSS/pMMR Advanced Colorectal Cance
Lead sponsor
Shanghai Junshi Bioscience Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
April 23, 2025
Completion date
February 13, 2027
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced colorectal cancer